– USA, CA – AristaMD, a leading digital health company that provides proprietary eConsult solutions that connect primary care providers with timely, documented specialist insights, today announced the addition of Ann Barnes, CEO of Intelligent Medical Objects, to its board of directors.
“We are honored to welcome Ann to our board of directors,” said CEO, Brooke LeVasseur. “Her track record speaks for itself. She is the rare combination of innovative entrepreneur and growth-oriented operator who knows how to build high-performing teams and exceed audacious goals. We know Ann will provide valuable perspectives and measurable impact to the company.”
Barnes brings over 30 years of experience achieving sustained revenue, profit and business growth within start-ups, Fortune 100 and mid-sized private equity-backed companies, with a unique combination of experience in the healthcare, financial and technology industries.
With the strategic addition of Barnes to the board of directors at AristaMD, the company is further positioned for continued and rapid growth that includes a wide range of product and process improvements that have significantly enhanced AristaMD’s capabilities and scalability. These efforts were the necessary groundwork that led to the company successfully completing its Series B funding round at $24 million in early 2020.
Barnes was referred to AristaMD through Break into the Boardroom, an initiative run by Oxeon Partners and Deerfield that promotes greater representation of female healthcare executives in the Boardroom.
About Ann Barnes
Ann Barnes joined IMO, the leading provider of medical terminology content and workflow software, two years ago. As CEO, she is responsible for the development and successful execution of IMO’s strategy, including translating that strategy into a tactical plan and leading the organization to achieving and exceeding metrics-based objectives. Prior to joining IMO, Barnes served as CEO at MedData, a leading provider of technology-enabled services to drive financial success for healthcare partners while creating a positive patient experience. During her time at MedData, Barnes successfully achieved revenue and EBITDA growth targets in excess of 30% year over year, spearheading and overseeing the company’s sale to publicly held MEDNAX.
“It’s already been a landmark year for AristaMD and I look forward to helping further accelerate commercial growth and cultivate ideas that progress the company’s mission,” said Ann Barnes. “Technology can, and should, facilitate collaboration between healthcare providers to expedite time to treatment, decrease costs and drive better patient outcomes. AristaMD is doing important work in these areas and I’m honored to serve on its board of directors.”
About AristaMD
AristaMD is focused on improving patient outcomes and reducing costs through more timely access to specialty care. Its eConsult platform provides a telehealth solution that empowers primary care providers to conduct electronic consults to significantly improve the patient referral process and allow faster access to timely, high-quality care. Designed to seamlessly integrate into physician referral workflows, the platform allows payers and providers to quickly and cost-effectively launch specialist eConsults using their own specialists or those provided by AristaMD’s contracted board-certified panel of experts. AristaMD’s platform has proven to significantly reduce the need for face-to-face visits while increasing patient satisfaction. AristaMD partners with healthcare stakeholders to ensure their success in the transition to value-based care.
For more information: https://www.aristamd.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.